Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01712178 · ClinicalTrials.gov registry record · Phase 2
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT01712178 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 100 participants.
The verdict
NCT01712178, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
Interventions
- BIOLOGICAL Adalimumab, current formulation
- BIOLOGICAL Adalimumab, new formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01712178
The ClinicalTrials.gov registry entry for NCT01712178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Adalimumab, current formulation is the first listed.
NCT01712178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01712178 about?
NCT01712178 is a clinical study titled "A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety". A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
What is the current status of trial NCT01712178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2012-06. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01712178?
The interventions under investigation include: Adalimumab, current formulation (BIOLOGICAL), Adalimumab, new formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT01712178?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.